Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)

Understanding of the Patient and Caregiver Experience of Wiskott-Aldrich Syndrome (WAS)

WAS is a rare primary immune deficiency disease caused by genetic mutation and is more common in males than females. The purpose of this study is to understand experiences of WAS subjects and caregivers to identify important concepts of interest that could be measured in future Phase IIIb trials. This is a qualitative cross-sectional study that will include a sample of approximately, 8 subjects with WAS and 13 caregivers of subjects with a diagnosis of WAS in the United States, United Kingdom and France. A 60 to 90 minute open-ended interview will be conducted over the telephone or video conference that will be audio-recorded for subsequent transcription. The aim of these interviews is to obtain subject and caregiver perspectives on the impact of WAS and its associated treatments on quality of life and experiences of living with WAS.

Study Overview

• Status: Completed
• Conditions: Wiskott-Aldrich Syndrome
• Intervention / Treatment: Other: Patient Interview guide; Other: Sociodemographic questionnaire; Other: Pediatric quality of life (PedsQL) questionnaire; Other: Clinical questionnaire; Other: Caregiver interview guide

• Study Type: Observational
• Enrollment (Actual): 19

Contacts and Locations

Study Locations

• United States
  • Pennsylvania
    • Collegeville, Pennsylvania, United States, 19426
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years to 30 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

• Sampling Method: Non-Probability Sample

Study Population

A convenience sample of approximately, 21 subjects with WAS and primary caregivers of WAS subjects will be included in the study.

Description

Inclusion Criteria:

Subjects:

• Male adolescents or young adults ranging in age from 12 through 30 years old.
• Diagnosis of WAS defined by WAS genetic mutation with a clinical score >=1 or self-reported disease severity.
• Subjects who are "conservatively managed" or have not received treatment for WAS; a maximum of 5 subjects who have received a hematopoietic stem cell transplant within the preceding two years.
• Able to read, speak, and understand English or French sufficiently to complete all assessments.
• Willing and able to participate in an audio-recorded, telephone or video conference session, including adherence to the interview instructions and completion of all questionnaires.
• Parent/guardian/patient signed informed consent.

Caregivers:

• Caregivers of children >=2 years of age diagnosed with WAS; at least 5 caregivers of subjects under the age of 8.
• Caregivers of subjects with a diagnosis of WAS defined by WAS genetic mutation with a clinical score >=1 or self-reported disease severity.
• Caregivers of subjects who are "conservatively managed" or have not received treatment for WAS; At least 2 caregivers of subjects who have received a hematopoietic stem cell transplant within the preceding two years.
• Caregivers are defined as primary caregiver.
• Able to read, speak, and understand English or French sufficiently to complete all assessments.
• Willing and able to participate in an audio-recorded, telephone or video conferencing interview session, including adherence to the interview instructions and completion of all questionnaires.
• Caregivers of Wiskott-Aldrich patients can be of any age or gender and do not have to follow the patient inclusion criteria, as long as their child/patient meets the inclusion criteria, as outlined.

Exclusion Criteria:

Subjects

• Subjects who have previously received gene therapy treatment Caregivers
• Caregivers of subjects who have previously received gene therapy treatment
• Professional caregivers (that is, at home nurse or equivalent).

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Group 1; Approximately 8 subjects with WAS between ages of 12 to 30 years will be included in Group 1.	Other: Patient Interview guide; The interviewer will conduct the interview for subjects with WAS using a semi-structured patient interview guide.; Other: Sociodemographic questionnaire; At the end of interview, subjects will be required to complete subject or caregiver versions of country-specific sociodemographic questionnaire.; Other: Pediatric quality of life (PedsQL) questionnaire; The PedsQL is a validated generic measure of health-related quality of life (HRQOL) in children, adolescents, and young adults with acute and chronic health conditions. At the end of interview, subjects will be required to complete subject or caregiver versions of PedsQL questionnaire.; Other: Clinical questionnaire; At the end of interview, subjects will be required to complete subject or caregiver versions of clinical questionnaire.
Group 2; Approximately 8 primary caregivers of subjects with WAS between ages 8 to 30 years will be included in Group 2.	Other: Sociodemographic questionnaire; At the end of interview, subjects will be required to complete subject or caregiver versions of country-specific sociodemographic questionnaire.; Other: Pediatric quality of life (PedsQL) questionnaire; The PedsQL is a validated generic measure of health-related quality of life (HRQOL) in children, adolescents, and young adults with acute and chronic health conditions. At the end of interview, subjects will be required to complete subject or caregiver versions of PedsQL questionnaire.; Other: Clinical questionnaire; At the end of interview, subjects will be required to complete subject or caregiver versions of clinical questionnaire.; Other: Caregiver interview guide; The interviewer will conduct the interview for caregivers of subjects with WAS using a semi-structured caregiver interview guide.
Group 3; Approximately 5 primary caregivers of subjects with WAS under the age of 8 years will be included in Group 3.	Other: Sociodemographic questionnaire; At the end of interview, subjects will be required to complete subject or caregiver versions of country-specific sociodemographic questionnaire.; Other: Pediatric quality of life (PedsQL) questionnaire; The PedsQL is a validated generic measure of health-related quality of life (HRQOL) in children, adolescents, and young adults with acute and chronic health conditions. At the end of interview, subjects will be required to complete subject or caregiver versions of PedsQL questionnaire.; Other: Clinical questionnaire; At the end of interview, subjects will be required to complete subject or caregiver versions of clinical questionnaire.; Other: Caregiver interview guide; The interviewer will conduct the interview for caregivers of subjects with WAS using a semi-structured caregiver interview guide.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of subject reported perspectives on WAS	Open-ended interviews will be conducted in adolescent and adult subjects to understand their perspective on WAS.	Up to 90 minutes
Number of caregiver reported perspectives on WAS	Open-ended interviews will be conducted in caregivers of subjects with WAS to understand their perspective on WAS.	Up to 90 minutes
Number of subject reported preventative measures taken to avoid infection and bleeding	The preventative measures taken to avoid infection and bleeding as reported by subjects during open-ended interviews will be summarized.	Up to 90 minutes
Number of caregiver reported preventative measures taken to avoid infection and bleeding	The preventative measures taken to avoid infection and bleeding as reported by caregivers during open-ended interviews will be summarized.	Up to 90 minutes
Number of subject reported awareness on the risk of disease	Open-ended interviews will be conducted in adolescent and adult subjects to understand their awareness on the risk of disease (that is, risk of future complications and potential rapid decline).	Up to 90 minutes
Number of caregiver reported awareness on the risk of disease	Open-ended interviews will be conducted in caregivers of WAS subjects to understand their awareness on the risk of disease (that is, risk of future complications and potential rapid decline).	Up to 90 minutes
Number of treatment sequences received by subjects	Open-ended interviews will be conducted to understand the treatments received by subjects in terms of sequencing.	Up to 90 minutes
Number of subject reported reasons for discontinuation or change in treatment option	Open-ended interviews will be conducted in adolescent and adult subjects to understand reasons for discontinuation or change in treatment option for WAS.	Up to 90 minutes
Number of caregiver reported reasons for discontinuation or change in treatment option	Open-ended interviews will be conducted in caregivers of WAS subjects to understand reasons for discontinuation or change in treatment option for WAS.	Up to 90 minutes
Analysis of tolerability of treatment by subjects	Open-ended interviews will be conducted in subjects and caregivers to understand the tolerability of WAS treatment by subjects.	Up to 90 minutes
Number of subject reported treatment burden	Open-ended interviews will be conducted in adolescent and adult subjects to analyze treatment burden for subjects.	Up to 90 minutes
Number of caregiver reported treatment burden	Open-ended interviews will be conducted in caregivers of WAS subjects to analyze treatment burden for caregivers.	Up to 90 minutes
Number of subject reported perspectives on the risk associated with treatment	Open-ended interviews will be conducted in adolescent and adult subjects to understand their perspective on the risks associated with each treatment.	Up to 90 minutes
Number of caregiver reported perspectives on the risk associated with treatment	Open-ended interviews will be conducted in caregivers of WAS subjects to understand their perspective on the risks associated with each treatment.	Up to 90 minutes
Number of key concepts of interest	Open-ended interviews will be conducted to identify the important concepts of interest that may be used in future clinical trials.	Up to 90 minutes

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Study record dates

Study Major Dates

• Study Start (Actual): January 24, 2018
• Primary Completion (Actual): September 14, 2018
• Study Completion (Actual): September 14, 2018

Study Registration Dates

• First Submitted: January 8, 2018
• First Submitted That Met QC Criteria: January 8, 2018
• First Posted (Actual): January 16, 2018

Study Record Updates

• Last Update Posted (Actual): March 14, 2019
• Last Update Submitted That Met QC Criteria: March 13, 2019
• Last Verified: March 1, 2019

More Information

Terms related to this study

• Keywords: Caregiver; France; Interview; United Kingdom; Wiskott-Aldrich Syndrome; United States; immune deficiency
• Additional Relevant MeSH Terms: Pathologic Processes; Immunologic Deficiency Syndromes; Immune System Diseases; Disease; Hematologic Diseases; Blood Coagulation Disorders, Inherited; Hemorrhagic Disorders; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Blood Coagulation Disorders; Leukopenia; Leukocyte Disorders; Primary Immunodeficiency Diseases; Lymphopenia; Syndrome; Wiskott-Aldrich Syndrome
• Other Study ID Numbers: 208034

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No